Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

By D. Sugiyama, H. Nishikawa, Y. Maeda, M. Nishioka, A. Tanemura, I. Katayama, S. Ezoe, Y. Kanakura, E. Sato, Y. Fukumori and 3 more. Proceedings of the National Academy of Sciences of the United States of America, 2013

619 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/805bfcf90b370224f98327baa740df8fb9768bd3

Citations in the corpus

• Regulatory T cells exhibit distinct features in human breast cancer (2016, neutral): “This has been demonstrated experimentally for CCR4, whose ligands CCL17 and/or CCL22 can be expressed by tumor cells or tumor associated myeloid cells (Curiel et al., 2004; Faget et al., 2011; Sugiyama et al., 2013).”